Mesa Labs Q2 revenue up 5%

Overview

• Mesa Laboratories fiscal Q2 revenue grows 5%, operating income rises 34.7%

• Net income for fiscal Q2 decreases 27.8% compared to prior year

• Biopharmaceutical Development and Calibration Solutions show strong growth despite CG challenges

Outlook

• Mesa expects sequential revenue growth in 3Q26

• Company plans to reinvest $0.9M savings into SDC for long-term growth

• Mesa anticipates continued revenue declines in China for FY26

Result Drivers

• BPD GROWTH - Biopharmaceutical Development division saw strong revenue growth driven by higher sales of Peptides instruments and delayed bookings from 1Q26

• COST REDUCTIONS - Mesa reduced annualized costs by $3.2M to align with global tariffs and currency headwinds, with $2.1M reductions in CG

• CG CHALLENGES - Clinical Genomics division faced a 58% revenue decline in China due to macroeconomic and regulatory headwinds

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Mesa Laboratories Inc is $88.50, about 16.2% above its November 5 closing price of $74.20

• The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 40 three months ago

Press Release: ID:nGNXfPL84

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.